Targeting a large potential market with unmet medical need

  • Global sales of topical over the counter non steroidal anti-inflammatory drugs (“NSAIDs”). US$ 2.9 billion1
  • US market alone worth over $1bn2.
    1st product launched in the US in 2008.
  • Demand for safe, effective and long lasting topical pain relief. Topical treatments are first line of treatment for osteoarthritis of the joints.
  • DermaSys® provides faster drug permeation, a key point of difference. Patient benefit by reducing dosing frequency.

Topical NSAIDS treatments are recommended by the National Institute for Health and Care Excellence (NICE) as the first line treatment for joint pain associated with osteoarthritis, in preference to oral NSAIDs, owing to concerns over systemic side effects caused by the long term use of oral NSAIDs.

Commercial strategy

In Europe, Futura has partnered with Thornton & Ross, a STADA AG subsidiary, for the manufacturing and distribution of TPR100 in the UK. A marketing authorisation filing was submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) by Thornton and Ross in July 2018 and in February 2019, the MHRA responded and raised questions requiring additional laboratory work. This work is progressing, and we expect Thornton & Ross to respond by the end of February 2020 within the timelines agreed with the MHRA. Futura is awaiting regulatory authorisation in the UK before progressing further with licensing discussions for further regions.


  1. 2015 IMS Health Estimate
  2. 2015 IMS Data source